Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$684.43 USD

684.43
8,362,231

+23.94 (3.62%)

Updated Aug 14, 2025 04:00 PM ET

After-Market: $691.03 +6.60 (0.96%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FTCS

Zacks Equity Research

Should iShares MSCI USA Min Vol Factor ETF (USMV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for USMV

Zacks Equity Research

Eli Lilly (LLY) Rises Yet Lags Behind Market: Some Facts Worth Knowing

by Zacks Equity Research

The latest trading day saw Eli Lilly (LLY) settling at $572, representing a +0.31% change from its previous close.

Ekta Bagri headshot

3 Cancer-Focused Biotechs That Appear Promising Bets for 2024

by Ekta Bagri

With the spotlight on oncology-focused companies in the biotech sector in 2023, we discuss three stocks that have a promising oncology portfolio/pipeline for 2024.

Zacks Equity Research

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PJP

Zacks Equity Research

The Zacks Analyst Blog Highlights Novo Nordisk, Eli Lilly, Vertex Pharmaceuticals, Regeneron and GSK

by Zacks Equity Research

Novo Nordisk, Eli Lilly, Vertex Pharmaceuticals, Regeneron and GSK are included in this Analyst Blog.

Kinjel Shah headshot

5 Big Drug Stocks That May Continue to Outperform in 2024

by Kinjel Shah

Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.

Zacks Equity Research

Eli Lilly (LLY) Dips More Than Broader Market: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed at $572.04 in the latest trading session, marking a -0.28% move from the prior day.

Zacks Equity Research

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XPH

Zacks Equity Research

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

by Zacks Equity Research

Sector ETF report for XPH

Zacks Equity Research

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Equity Research

LLY Down as Patients Regain Weight After Stopping Zepbound

by Zacks Equity Research

Full results from a late-stage study show that patients who stopped taking Eli Lilly's (LLY) weight-loss drug for over a year slowly started to regain their lost weight.

Zacks Equity Research

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

by Zacks Equity Research

Sector ETF report for IHE

Zacks Equity Research

Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?

by Zacks Equity Research

Sector ETF report for FHLC

Zacks Equity Research

Eli Lilly (LLY) Rises Higher Than Market: Key Facts

by Zacks Equity Research

The latest trading day saw Eli Lilly (LLY) settling at $598.05, representing a +1.66% change from its previous close.

Kinjel Shah headshot

Pharma Stock Roundup: ABBV to Buy CERE, JNJ's 2024 View, LLY & NVS Get FDA Nod

by Kinjel Shah

AbbVie (ABBV) offers to acquire Cerevel Therapeutics for $8.7 billion. J&J (JNJ) announces sales and earnings growth expectations for 2024.

Zacks Equity Research

Zacks Market Edge Highlights: SAIC, ANET, LLY, PFE and SIG

by Zacks Equity Research

SAIC, ANET, LLY, PFE and SIG have been highlighted in this Market Edge article.

Tracey Ryniec headshot

Will There Be a Recession in 2024?

by Tracey Ryniec

Tracey Ryniec and John Blank examine whether a recession is looming and how to invest in the new year.

Zacks Equity Research

Is it a Good Idea to Invest in AC Immune (ACIU) Stock Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in AC Immune (ACIU) stock now may turn out to be a prudent move.

Zacks Equity Research

Lilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca

by Zacks Equity Research

Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.

Zacks Equity Research

Roche (RHHBY) to Acquire Obesity Drug Maker Carmot for $2.7B

by Zacks Equity Research

Roche (RHHBY) aims to enter the promising and much-in-demand obesity drug market with the acquisition of Carmot Therapeutics, Inc. for $2.7 billion.

Zacks Equity Research

Altimmune (ALT) Rises 83% on Successful Phase II Obesity Study

by Zacks Equity Research

Altimmune (ALT) reports positive top-line data from its 48-week phase II MOMENTUM study of obesity drug candidate, pemvidutide. The stock gains 83%.

Zacks Equity Research

Pfizer (PFE) Stock Down 5% as Obesity Drug Fails in Phase II

by Zacks Equity Research

The failure of the phase IIb study on danuglipron is a significant blow to Pfizer's (PFE) efforts to take a share of the growing market of GLP-1 drugs for treating obesity.

Zacks Equity Research

Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why

by Zacks Equity Research

Annovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease.

Zacks Equity Research

Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.